Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
of sertaconazole, terbinafine and luliconazole in patients with dermatophytoses.83 patients with tineacorporis and tinea cruris infections were enrolled in this multicentre, randomized, open label parallel study. The initial 'Treatment Phase' involved three groups receiving either sertaconazole 2% cream applied topically twice daily for four weeks, terbinafine 1% cream once daily for two weeks, luliconazole 1% cream once daily for two weeks. At the end of treatment phase, there was a 'Follow-up Phase' at end
/20). Dermatophytosis was more frequent in women (58%; 38/66). Fifty-two percent (21/38) of the cases were children with an average age of 8 years. The most frequent clinical presentation was Tineacorporis (55%, 36/66). For the cases in which the dermatophyte agent was not isolated, we discuss the factors that may be interfering with isolation. Tineacorporis occurred more frequently observed when T. mentagrophytes and T. rubrum were the major etiologic agents.
patients in Tehran, Isfahan, Mazandaran and Guilan provinces. The isolates were identified using macro/micro-morphological criteria and electrophoretic patterns of PCR amplicons of BT2after digestion with each of the restriction enzymes FatI, HpyCH4V, MwoI and Alw21I.Among the patients, 59.2% were male and 40.8% female. The most prevalent clinical form was tinea pedis (42.4%), followed by tinea cruris (24.2%), tinea unguium (12.3%), tineacorporis (10.8%), tinea faciei (4%), tinea manuum (3.14%), tinea (...) capitis (3%) and tinea barbae (0.16%), respectively. Trichophyton interdigitale ranked the first, followed by T. rubrum, Epidermophyton floccosum, Microsporum canis, T. tonsurans, T. erinacei and T. violaceum (each 0.49%) and the less frequent species were T. schoenleinii, M. gypseum and T.anamorph of Arthroderma benhamiae (each 0.16%). A case of scalp infection by E. floccosum was an exceptional event in the study. No case of T. verrucosum was found.Trichophyton species and E. floccosum are yet
, tineacorporis, neutrophilic eccrine hidradenitis or eosinophilic pustular folliculitis (Ofuji syndrome). 2.8 Known diagnosis of DIRA. 2.9 History of allergic reactions attributed to compounds of similar chemical or biologic composition to anakinra or other agents used in study. Known hypersensitivity to CHO-cell derived biologics or any components of anakinra. 2.10 Treatment with a live virus vaccine during the 3 months prior to baseline visit. No live vaccines will be allowed throughout the course (...) to the patient to enter the study. 2.7 Other defined dermatologic conditions which may include pustules as part of the clinical presentation, but which clinically and/or histologically do not resemble pustular psoriasis. Examples include, but are not limited to acute generalized exanthematous pustulosis (AGEP, a drug-induced pustular dermatosis typically caused by beta-lactam antibiotics, tetracyclines, oral antifungals and other drugs), bacterial or fungal folliculitis, cutaneous candidiasis, tinea pedis
to adversely affect the outcome of the study History or evidence of significant cardiac, renal, hepatic or endocrine disease Significant hypersensitivity or allergy, as judged by the investigator Immunocompromised patients Lice or scabies Tineacorporis Hypersensitivity to the ingredients of the vehicle The presence of prominent tattoos at sites of application of DPK-060 1% or placebo ointment Donation of blood, exceeding 450 mL, during the three months prior to first dose Participation in a clinical study
a written informed consent form and a Health Insurance Portability and Accountability Act (HIPAA) authorization form, which must be obtained prior to participation in this study. The HIPAA authorization may be incorporated in the informed consent form. Also, the subject's assent must be obtained and documented. Exclusion Criteria: Any inflammatory skin disease in the treatment area that may confound the evaluation of the plaque psoriasis (eg, atopic dermatitis, contact dermatitis, tineacorporis
and supported by the medical history and normal or not clinically significant abnormal vital signs (blood pressure and pulse). Exclusion Criteria: Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis. Other inflammatory skin disease that may confound the evaluation of the plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tineacorporis). Presence of pigmentation, extensive scarring, pigmented lesions or sunburn which could
corporis.Fungal DNA was extracted from hair and skin samples that were confirmed to be positive by direct mycological examination. Dermatophytes were identified by the sequence of a 28S ribosomal DNA subunit amplicon generated by nested PCR.Nested PCR was found to be necessary to obtain amplicons in substantial amounts for dermatophyte identification by sequencing. The results agreed with those of classical mycological identification in 14 of 23, 6 of 10, and 20 of 23 cases of tinea capitis, tineacorporis (...) and tinea pedis, respectively, from which a dermatophyte was obtained in culture. In seven of the 56 cases, another dermatophyte was identified, revealing previous misidentification. A dermatophyte was identified in 12 of 18, three of five, and four of nine cases of tinea capitis, tineacorporis and tinea pedis, respectively, in cases in which no dermatophyte grew in culture.Although the gold standard dermatophyte identification from clinical samples remains fungal cultures, the assay developed
Tolnaftate (tinactin), a new topical antifungal agent. Using the double-blind technique, patients with tinea pedis, tinea cruris and tineacorporis were treated with either (a) 1% tolnaftate in a cream base or (b) the cream base.Twenty-four of 29 patients (82.7%) using 1% tolnaftate cream demonstrated clearing or great improvement of their lesions after three weeks of therapy, whereas only two of nine (22.2%) had similar results using the placebo.
improvement, in tinea pedis, tinea cruris, tineacorporis, pityriasis versicolor, and cutaneous candidasis. Furthermore, species identification established the efficacy of clotrimazole against Trichophyton rubrum, T mentagrophytes, Epidermophyton floccosum, Microsporum canis, Malassezia furfur (Pityrosporum orbiculare), and Candida albicans. Safety was demonstrated by the low incidence of possibly drug-related adverse experiences, namely, 19 (2.7%) of 699 patients who were treated with clotrimazole
assigned to 3 groups and received: treatment with combination of 2% KZC and 2% TET cream (KCZ + TET group), or only 2% KZC cream (KCZ group), or 2% TET cream (TET group). Patients with tineacorporis and/or tinea cruris were treated for 2 weeks, separately. The patients with tinea pedis and/or tinea manuum were treated for 4 weeks.Compared with KZC alone, combined use of KZC and TET showed lower MICs against clinical isolates of dermatophytes (P<0.05 for all). In the patients with tineacorporis (...) and/or tinea cruris, the rates of overall cure (clinical cure plus mycologic clearance) were 81.25% vs. 33.33% for combined treatment and KZC monotherapy, respectively, after 4 weeks. All clinical indices were significantly different between the combination therapy and only KCZ therapy groups (P<0.05). Among the patients with tinea pedis and/or tinea manuum after 4 weeks treatment, the overall cure rates in the KCZ + TET group and KCZ group were 75.00% vs. 40.00%, respectively. In the KCZ + TET group, all
diseases such as: pityriasis rosea, tineacorporis, psoriasis, nummular eczema, atopic dermatitis, drug reaction, erythema migrans and other . Differential diagnosis [ ] Treatment [ ] No treatment is usually needed as they usually go away anywhere from months to years. The lesions may last from anywhere between 4 weeks to 34 years with an average duration of 11 months. If caused by an underlying disease or malignancy, then treating and removing the disease or malignancy will stop the lesions (...) (April 2007). "Erythema annulare centrifugum secondary to treatment with finasteride". J Drugs Dermatol . 6 (4): 460–3. . Weyers W, Diaz-Cascajo C, Weyers I (December 2003). . Am J Dermatopathol . 25 (6): 451–62. : . . Enta T (November 1996). . Can Fam Physician . 42 : 2148, 2151. . . External links [ ] Classification - : - : : External resources : : Diseases of the skin and appendages by morphology Growths Pigmented and subcutaneous With epidermal involvement Eczematous tinea ( ) Hypopigmented
. Retrieved on February 18, 2010 2010-02-18 [ ] Gupta, A; Chaudhry, M; Elewski, B (2003). "Tineacorporis, tinea cruris, tinea nigra, and piedra". Dermatologic Clinics . 21 (3): 395–400, v. : . . , . Retrieved on 2010-02-18 Michetti, P M; Rossi, R; Bonanno, D; Tiesi, A; Simonelli, C (2005). "Male sexuality and regulation of emotions: a study on the association between alexithymia and erectile dysfunction (ED)". International Journal of Impotence Research . 18 (2): 170–4. : . . . 2018-09-06. Coretti G
) or tinea cruris (ringworm of the groin region), or tineacorporis (ringworm in other body areas); Direct mycological exam positive for fungi; Exclusion Criteria: Pregnant women or nursing mothers; Use of topical or oral antifungal; Use of steroids; Allergy or hypersensitivity to any component of product; Clinical cases of tinea infection by bacteria and / or eczema, tinea extensive and onychomycosis. Contacts and Locations Go to Information from the National Library of Medicine To learn more about (...) . Condition or disease Intervention/treatment Phase Fungal Infections Tinea Pedis Tinea Cruris TineaCorporis Drug: Clotrimazole Phase 3 Detailed Description: Study Clinical, multicenter, Phase III, to evaluate the efficacy and safety of 10mg/g tolnaftate cream in the treatment of patients with fungal infections such as Tinea foot, Tinea and Tinea crural body. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 90 participants
and then as tineacorporis. In the second case, subacute cutaneous lupus was considered but lupus antibodies were negative. In the third case, the annular erythema was promptly recognized and biopsied. Histology in all three cases revealed identical findings of invasive ductal carcinoma involving the lymphatics of the skin. Immunohistochemical staining of the carcinoma was positive for human epidermal growth factor receptor 2 but negative for oestrogen and progesterone receptors. Annular erythema can pose
screened to assess their general skin health conditions. All children were examined naked in good day light. To record data we used an EPIinfo questionnaire.A total of 1104 children were screened. We registered a total number of 1086 dermatological problems, 876 of them were of infective origin mainly represented by fungal infections (36.1%). Tinea capitis represented 76% of the cases, tineacorporis 27% and tinea unguium 8%. Head lice affected 345 children. Viral infections accounted for 12%, most